STAAR Surgical supplies implantable lenses for vision correction, serving ophthalmic surgeons and clinics globally with proprietary tech.
On May 28, 2026, Staar Surgical Co (STAA) shares fell 7.3% to a current price of $29.08. This decline comes amidst a volatile trading period, as the stock has e
STAAR Surgical Company (STAA) Discusses Differentiation of EVO ICL Technology and Market Trends in Refractive Surgery Transcript
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, t
STAAR Surgical Company delivered a robust 1Q26 beat, with revenue up 119% YoY to $93.5M and a swing to $5.2M net income. China's market rebound, normalized inventory, and rapid EVO+ ICL adoption drove
Staar Surgical shares catapulted Thursday after the eye surgery outlet obliterated first-quarter profit expectations.
STAAR Surgical Company (STAA) Q1 2026 Earnings Call Transcript

STAAR Surgical Q1 Earnings Call Highlights

12:14am, Thursday, 14'th May 2026
STAAR Surgical NASDAQ: STAA said its first quarter of 2026 marked a sharp rebound in sales and profitability, driven by strong demand in China, continued growth in the U.S. and tighter cost controls f
While the top- and bottom-line numbers for Staar Surgical (STAA) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics co
Staar Surgical (STAA) came out with quarterly earnings of $0.38 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to a loss of $0.52 per share a year ago.
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, t
On May 01, 2026, Staar Surgical Co (STAA) shares rose 3.1% today, bringing the current price to $27.19. Over the past 52 weeks, the stock has fluctuated between
McKesson (MCK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Staar Surgical (STAA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
STAAR Surgical (STAA) stock surged more than 25% on Thursday after the ophthalmic implant maker projected first-quarter net sales would top $90 million, more th
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE